The paper Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study was authored by Yuya Koide, Takehiro Kato, Makoto Hayashi, Hisashi Daido, Takako Maruyama, Takuma Ishihara, Kayoko Nishimura, Shin Tsunekawa, and Daisuke Yabe on behalf of G-DIET Investigators
Promising results have been observed for the GLP-1/GIP agonist LY3298176 in overweight or obese people with T2D, noting a weight loss between 0.9 and 11.3 kg in participants using the dual agent compared with 0.4 kg and 2.7 kg in those using placebo or dulaglutide respectively [52]
Anthem is one of the largest health insurance providers in the United States, operating under the Blue Cross Blue Shield umbrella in multiple states
Dosing errors have resulted from patients measuring and self-administering incorrect doses of the drug and health care providers miscalculating doses of the drug
Unlike oral medications absorbed through the gut, injections rely on a consistent layer of healthy fat tissue for steady, predictable drug absorption
Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight [Wyatt MD, Holly R., Hill PhD, James O.] on Amazon.com
&srotate=0)
